SCHEMBL5000417

SCHEMBL5000417

NC(=O)c1csc(-c2ccnc(N)n2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 13/20 0.51
KDM4B O94953 1/20 0.50
KDM5C P41229 1/20 0.50
KDM5B Q9UGL1 1/20 0.50
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
DBF4 Q9UBU7 4/20 0.44
CCNE1 P24864 4/20 0.44
CDK2 P24941 4/20 0.44
ROCK1 Q13464 2/20 0.43
HSP90AA1 P07900 1/20 0.43
CCNT1 O60563 2/20 0.42
CDK9 P50750 2/20 0.42
IKBKB O14920 1/20 0.42
JAK2 O60674 1/20 0.42
CCNB2 O95067 1/20 0.42
CCNE2 O96020 1/20 0.42
PRKCB P05771 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3322652 0.76 KDM4E (0.56) CDC7KDM4EALDH1A1CCNE1CDK2
SCHEMBL5000362 0.74 CDC7 (0.54) CDC7KDM4EALDH1A1DBF4CCNE1
SCHEMBL3792630 0.72 CDC7 (0.47) CDC7KDM4BKDM5CKDM5BMKNK2
SCHEMBL31396451 0.72 JAK2 (0.48) CDC7MKNK2DBF4CCNE1CDK2
SCHEMBL13992625 0.71 KDM5C (0.49) KDM4BKDM5CKDM5BKDM4EALDH1A1
SCHEMBL13992623 0.71 KDM4B (0.40) KDM4BKDM5CKDM5BKDM4EALDH1A1
SCHEMBL27666055 0.70 CDC7 (0.64) CDC7KDM4EALDH1A1DBF4CCNE1
SCHEMBL1445252 0.70 MIF (0.38) KDM4BKDM5CKDM5BMKNK1MKNK2
SCHEMBL27932338 0.69 CDC7 (0.47) CDC7CCNE1CDK2ROCK1CCNT1
SCHEMBL4187180 0.68 CDC7 (1.00) CDC7CCNE1CDK2HSP90AA1CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7470701-B2 Substituted 2,5-heterocyclic derivatives NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-12-30 US disclosed
US-20080255120-A1 SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-10-16 US disclosed
EP-1732919-A1 SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS CHIRON CORPORATION (US) 2006-12-20 EP disclosed
US-20050256121-A1 e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma CHIRON CORPORATION (US) 2005-11-17 US disclosed
WO-2005095386-A1 SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS CHIRON CORPORATION (US) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256121-A1 e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma MALT1, AKT1, PIK3CA CDC7 690/4885KDM4B 1552/4885KDM5C 1064/4885
US-20080255120-A1 SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES CYP3A5, ABCG2, ABCB1 CDC7 3871/4885KDM4B 2772/4885KDM5C 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.